QualityStocks

[QualityStocks]

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) Lead Clinical Candidate Development Advances Following Promising Phase IIa Results

Clinical-stage biotechnology company BriaCell Therapeutics (TSX.V: BCT) (OTCQB: BCTXF) has achieved proof of concept and recently reported promising results from its Phase IIa study of its lead clinical candidate, Bria-IMT. An article further discussing the company reads, “A total of 31 patients with advanced stage breast cancer were enrolled in the Phase II Bria-IMT monotherapy study. The proof of concept and mechanism of action work is based on the results observed in the first 20 patients, while assessment of the remaining 11 patients is still in progress. …The preliminary data seems to confirm the company’s HLA Matching Hypothesis and support its strategy for the development of Bria-OTS, the first off-the-shelf personalized immunotherapy for advanced breast cancer, designed to provide treatment without the high costs and difficult manufacturing generally associated with personalized therapies. The technology is applicable to other types of cancer, as well.” A combination study with immune checkpoint inhibitors is in the works and enrollment is already open.

To view the full article, visit http://ibn.fm/ww3Mw

About BriaCell
BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizumab [Keytruda; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers Squibb Company]. The combination study is listed in ClinicalTrials.gov as NCT03328026. BriaCell is developing Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS, which is expected to cover over 90 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense, and complex manufacturing logistics associated with other personalized immunotherapies. For more information, visit the company’s website at www.BriaCell.com.